Cytek Biosciences, Inc (CTKB) Prices 16.7M Share IPO at $17/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Cytek Biosciences (CTKB) IPO Opens 24% Higher
July 23, 2021 12:10 PM EDTToday's IPO for Cytek Biosciences, Inc. (Nasdaq: CTKB) opened for trading at $21.10 after pricing 6,749,330 shares of its common stock at a price to the public of $17.00 per share.
Morgan Stanley, Goldman Sachs & Co. LLC, Piper Sandler & Co. and Cowen are acting as joint book running managers... More
